Desmoplastic Small Round Cell Tumor (DSRCT) –Varied Presentation

Tanushri Mukherjee*, Soma Mukherjee2 and Rajadutta3

1Department of Pathology, Command hospital Chandimandir, India
2Department of Obs Gynae, AIIMS Bhopal, India
3Department of surgery, Command hospital, India

Submission: September 21, 2017; Published: October 27, 2017

*Corresponding author: Tanushri Mukherjee, Oncopathologist, Department of Pathology Command hospital Chandimandir, India, Email: tanujamukherjee@yahoo.com

Introduction

Desmoplastic small round cell tumor (DSRCT) is a small round cell tumor usually presents as abdominal lump or omental metastasis [1]. DSRCT is aggressive malignant neoplasm of young male adults and distant metastases occurs at the time of diagnosis [2]. EWS-WT1 fusion protein and (11;22) (p13;q12) translocation, the N-terminal domain of EWS to the C-terminal DNA-binding domain of WT1 is the pathogenesis resulting in an aberrant transcription factor.

Desmoplastic small round cell tumor (DSRCT) was first described in 1989 by [3]. Tumor cells co-express epithelial, mesenchymal and neuronal markers and are thought to originate from a mesothelial or sub mesothelial progenitor cell with the potential to undergo multilineage differentiation. DSRCT despite surgery and chemotherapy yields a poor prognosis and five year survival is 15% [4].

Case Report

32 years old serving soldier with history of fullness of abdomen, nausea and poor appetite for 7 days. Known case of Primary sclerosing cholangitis, chronic liver disease with portal hypertension and idiopathic ulcerative colitis. On admission-Conscious, afebrile, icterus present. P/A soft nontender, Hepatomegaly present with no splenomegaly, with sluggish bowel sounds. B.P -108/90mmHg, Pulse 100/min, RR 24/min. CVS–Heard sounds present with no murmur or additional sounds. Initial investigations-Hemoglobin 14.1gm/dl, TLC 20500/cumm with 75% neutrophils, platelets 245000/cumm. Total Bilirubin 5.1mg/dl, Direct bilirubin 3.0mg/dl, serum AST/ALT 822 IU/LAST 730 IU/L, ALP 184 IU/L Urea 93mg/dl, creatinine 1.3mg/dl, NA/K 142/4.5 meq/L USG abdomen showed hepatomegaly with coarse echotexture, hemangiomas liver; portal hypertension, thickened colonic wall. Treatment was started on IV fluids, in magnex, injilagyl, injemset, inj albumin, injrantac, injVitK, Tabsulfalsalazine, tablets helcal, folate. Hb 12.2g/dl TLC 28300/cumm, DLC P88L12. Platelets 1.35 /cumm. Total bilirubin 9.3mg/dl Direct bilirubin -5.4mg/dl, ALT 702IU/L AST 712 IU/L ALP 320 IU/L Urea(mg/dl) 123mg/dl, Creatinine(mg/dl) 1.9mg/dl. Subsequently he suffered cardiac arrest. Postmortem examination was conducted. Main gross finding was massively enlarged Liver 3350gms. yellow colored protuberant nodular tumor. Cut surface of the liver showed tumor nodules measuring 7x4 cm, and 5x5 cm. Histologic examination shows small cells that can be round, ovoid or spindled usually grouped in clumps, cords, nests or sheets. These cells contain hyperchromatic nuclei with condensed chromatin and eosinophilic cytoplasm. Mitotic figures are common. The extensive collagenous stroma is characteristic. Microscopically metastasis was noticed in both lungs, intestines and omentum. Figures 1-6. Immuno histochemical markers positivity seen for Epithelial pancytokeratin, epithelial membrane antigen, vimentin, neuron-specific enolase, WT1. Molecular Analysis revealed EWS-WT1 reciprocal translocation on chromosome 22 at 22q12

Discussion

DSRCT presents as an aggressive tumor with abdominal mass. The sites of disease include pleura, ethmoid sinuses, scalp, hand, posterior cranial fossa, pancreas, ovary, paratesticular and kidney. Liver metastases are common at diagnosis and relapse; other distant sites include lymph nodes, lung and bones [6-10]. More than 40% of patients have distant metastases at the time of diagnosis, mostly located in the liver, lungs, and lymph nodes. The 5-year survival of less than 15%. Treatment options include surgery, radiotherapy, chemotherapy with or without stem cell transplantation, and recently introduced molecularly targeted therapies [11-16]. Unfortunately there is no standard
Current treatment modalities are highly toxic, with numerous side effects, and are not sufficiently effective. Recent advances in the understanding of the molecular pathophysiology of DSRCT should lead to the development of effective molecularly targeted therapies with fewer side effects. For example, Leflunomide (SU101) is a platelet-derived growth factor (PDGF) receptor...
inhibitor that acts by blocking PDGF-stimulated receptor auto phosphorylation and subsequent cell-cycle progression. This compound also inhibits dihydroorotate dehydrogenase thus interfering with pyrimidine bio synthesis.

Conclusion

DSRCT is a highly aggressive small round blue cell tumor of young male adults with a dismal prognosis for which the ideal therapeutic modality is yet to be determined. Current therapeutic approaches remain highly toxic and have not achieved complete disease control. The development of molecularly targeted agents, likely in combination with conventional approaches, could potentially have significant impact on the treatment of this disease.

References